Tags

Type your tag names separated by a space and hit enter

Fracture reducing potential of hormone replacement therapy on a population level.
Maturitas 2006; 54(3):285-93M

Abstract

OBJECTIVES

To study the fracture reducing potential of hormone replacement therapy (HRT) at a population level, the effect of age on the fracture reducing potential of HRT, and to examine whether socio-economic factors confound the effects of HRT on fracture risk.

SUBJECTS AND METHODS

Case-control study. All women who sustained any fracture during the year 2000 in Denmark served as cases (n=64,548). For each case, three age-matched controls were randomly drawn from the background population (n=193,641). The main exposure was the average daily dose of HRT (expressed as defined daily doses DDD/day). Adjustments were made for co-morbidity, socio-economic factors, and prior fracture.

RESULTS

A fracture risk reduction was seen in women aged>or=50 years using >or=0.3 DDD/day. The risk reduction for any fracture was larger in women aged>or=60 years (0.3-0.99 DDD/day: odds ratio (OR)=0.77, 95% confidence intervals (CI): 0.73-0.82, >or=1 DDD/day: OR=0.61, 95% CI: 0.56-0.67) than in women aged 50-59 years (0.3-0.99 DDD/day: OR=0.92, 95% CI: 0.85-0.99, >or=1 DDD/day: OR=0.77, 95% CI: 0.70-0.84). Larger risk reductions were seen for Colles' fractures (age 50-59 years: OR=0.64 for 0.3-0.99 DDD/day, and OR=0.57 for >or=1 DDD/day, age>or=60 years: OR=0.52 for 0.3-0.99 DDD/day, and OR=0.40 for >or=1 DDD/day). Adjustment only changed the estimates little. No difference between oral and dermal preparations could be found.

CONCLUSIONS

Hormonal replacement therapy possesses a fracture-reducing potential at population level even at dosages lower than usually recommended. The risk reduction was larger with advancing age for any fracture and Colles' fractures.

Authors+Show Affiliations

Department of Endocrinology and Metabolism C, Aarhus Sygehus, Aarhus University Hospital, The Osteoporosis Clinic, Aarhus Amtssygehus, Tage Hansens Gade 2, DK-8000 Aarhus C, Denmark. p-vest@post4.tele.dkNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16413706

Citation

Vestergaard, Peter, et al. "Fracture Reducing Potential of Hormone Replacement Therapy On a Population Level." Maturitas, vol. 54, no. 3, 2006, pp. 285-93.
Vestergaard P, Rejnmark L, Mosekilde L. Fracture reducing potential of hormone replacement therapy on a population level. Maturitas. 2006;54(3):285-93.
Vestergaard, P., Rejnmark, L., & Mosekilde, L. (2006). Fracture reducing potential of hormone replacement therapy on a population level. Maturitas, 54(3), pp. 285-93.
Vestergaard P, Rejnmark L, Mosekilde L. Fracture Reducing Potential of Hormone Replacement Therapy On a Population Level. Maturitas. 2006 Jun 20;54(3):285-93. PubMed PMID: 16413706.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fracture reducing potential of hormone replacement therapy on a population level. AU - Vestergaard,Peter, AU - Rejnmark,Lars, AU - Mosekilde,Leif, Y1 - 2006/01/18/ PY - 2005/05/09/received PY - 2005/08/17/revised PY - 2005/12/07/accepted PY - 2006/1/18/pubmed PY - 2006/10/27/medline PY - 2006/1/18/entrez SP - 285 EP - 93 JF - Maturitas JO - Maturitas VL - 54 IS - 3 N2 - OBJECTIVES: To study the fracture reducing potential of hormone replacement therapy (HRT) at a population level, the effect of age on the fracture reducing potential of HRT, and to examine whether socio-economic factors confound the effects of HRT on fracture risk. SUBJECTS AND METHODS: Case-control study. All women who sustained any fracture during the year 2000 in Denmark served as cases (n=64,548). For each case, three age-matched controls were randomly drawn from the background population (n=193,641). The main exposure was the average daily dose of HRT (expressed as defined daily doses DDD/day). Adjustments were made for co-morbidity, socio-economic factors, and prior fracture. RESULTS: A fracture risk reduction was seen in women aged>or=50 years using >or=0.3 DDD/day. The risk reduction for any fracture was larger in women aged>or=60 years (0.3-0.99 DDD/day: odds ratio (OR)=0.77, 95% confidence intervals (CI): 0.73-0.82, >or=1 DDD/day: OR=0.61, 95% CI: 0.56-0.67) than in women aged 50-59 years (0.3-0.99 DDD/day: OR=0.92, 95% CI: 0.85-0.99, >or=1 DDD/day: OR=0.77, 95% CI: 0.70-0.84). Larger risk reductions were seen for Colles' fractures (age 50-59 years: OR=0.64 for 0.3-0.99 DDD/day, and OR=0.57 for >or=1 DDD/day, age>or=60 years: OR=0.52 for 0.3-0.99 DDD/day, and OR=0.40 for >or=1 DDD/day). Adjustment only changed the estimates little. No difference between oral and dermal preparations could be found. CONCLUSIONS: Hormonal replacement therapy possesses a fracture-reducing potential at population level even at dosages lower than usually recommended. The risk reduction was larger with advancing age for any fracture and Colles' fractures. SN - 0378-5122 UR - https://www.unboundmedicine.com/medline/citation/16413706/Fracture_reducing_potential_of_hormone_replacement_therapy_on_a_population_level_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0378-5122(05)00377-4 DB - PRIME DP - Unbound Medicine ER -